Status: Recruiting

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

Participants needed: 20

Trial details

Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: The General Hospital of Western Theater CommandUpdated: Jun 9, 2026Locations: 1

Eligibility criteria

The subject or their legally authorized representative has provided written info... [+12]

Severe cardiac dysfunction with left ventricular ejection fraction (LVEF) < 50% [+10]

Status: Not yet recruiting

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.

Participants needed: 20

Trial details

Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Affiliated Hospital to Academy of Military Medical SciencesUpdated: Apr 8, 2026Locations: 1

Eligibility criteria

Confirmation for either BCMA or CD19 positivity using immunohistochemistry or fl... [+10]

Severe heart failure with left ventricular ejection fraction <50% [+9]

Status: Not yet recruiting

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms.

Participants needed: 20

Trial details

Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chinese PLA General HospitalUpdated: Jul 22, 2025Locations: 2

Eligibility criteria

Age 18-75 years, [+6]

Severe heart failure with left ventricular ejection fraction <50%; [+8]